Skip to content
Home/Companies/Biotechnology/Dilepix
Dilepix

Dilepix

Biotechnology·France·Active·6yr hold
Entry
2020
Hold
6yr
Status
Active

Who owns Dilepix?

Dilepix is currently owned by Elaia Partners through Elaia Alpha II (2020 vintage), since 2020.

Hand-verified · updated 2026-04-21

Elaia Partners
Investor
Elaia Partners
Elaia Alpha II · 2020 · VC

Key facts

HQFrance
SectorBiotechnology
Websitewww.dilepix.com

More from Elaia Alpha II

Other portfolio companies in the same fund.

Alice & Bob
Alice & Bob
Active
Data & AnalyticsFrance· 2022
Arsen
Arsen
Active
CybersecurityFrance· 2022
Aviwell
Active
BiotechUS· 2022
Corporatings
Corporatings
Active
Data & AnalyticsFrance· 2022
Giskard
Giskard
Active
Data & AnalyticsFrance· 2022
Kheops
Kheops
Active
Data & AnalyticsFrance· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Dilepix

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Dilepix?

0 strategic and 120financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Dilepix.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue